| Gray, Robert J |
Dana-Farber Cancer Inst
United States |
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV) |
3U01CA233169-05S1 |
|
Rachel Altshuler, Ph.D. |
| Grimm, Lars J |
Duke University
United States |
Dynamic imaging and tissue biomarker models to delineate indolent from aggressive breast calcifications |
5R01CA271237-02 |
PAR-19-264 (R01 Clinical Trial Optional) |
Richard Mazurchuk, Ph.D. |
| Grogan, Eric L |
Vanderbilt University Medical Center
United States |
Clinical Utility of a Combined Biomarker Approach to Diagnose Lung Cancer |
5U01CA152662-12 |
|
Guillermo Marquez, Ph.D. |
| Grogan, Eric L |
Vanderbilt University Medical Center
United States |
Clinical Utility of Biomarkers Driven Management of Indeterminate Pulmonary Nodules |
5R01CA252964-04 |
|
Claire Zhu, Ph.D. |
| Gross, Howard M |
Dayton Clinical Oncology Program
United States |
Dayton Clinical Oncology Program |
5UG1CA189957-10 |
|
Brandy Heckman-Stoddard, Ph.D., M.P.H. |
| Gross, Howard M |
Dayton Clinical Oncology Program
United States |
Dayton Clinical Oncology Program |
5UG1CA189957-10 |
|
Brandy Heckman-Stoddard, Ph.D., M.P.H. |
| Gross, Howard M |
Dayton Clinical Oncology Program
United States |
Dayton Clinical Oncology Program |
5UG1CA189957-10 |
|
Brandy Heckman-Stoddard, Ph.D., M.P.H. |
| Gross, Howard M |
Dayton Clinical Oncology Program
United States |
Dayton Clinical Oncology Program |
5UG1CA189957-10 |
|
Brandy Heckman-Stoddard, Ph.D., M.P.H. |
| Gross, Howard M |
Dayton Clinical Oncology Program
United States |
Dayton Clinical Oncology Program |
5UG1CA189957-10 |
|
Brandy Heckman-Stoddard, Ph.D., M.P.H. |
| Gross, Howard M |
Dayton Clinical Oncology Program
United States |
Dayton Clinical Oncology Program |
5UG1CA189957-10 |
|
Brandy Heckman-Stoddard, Ph.D., M.P.H. |